--manuscript draft-- - indian academy of pediatrics (iap) · --manuscript draft --manuscript...
TRANSCRIPT
Indian Pediatrics
Adverse Event Following Immunization (AEFI) Surveillance in India: IAP's Perspectives--Manuscript Draft--
Manuscript Number:
Full Title: Adverse Event Following Immunization (AEFI) Surveillance in India: IAP's Perspectives
Article Type: Perspective
Corresponding Author: Vipin M Vashistha, MDMangla hospital & research centerBijnor, Uttar pradesh INDIA
Corresponding Author SecondaryInformation:
Corresponding Author's Institution: Mangla hospital & research center
Corresponding Author's SecondaryInstitution:
First Author: Amarjeet Chitkara, MD, DNB.
First Author Secondary Information:
Order of Authors: Amarjeet Chitkara, MD, DNB.
Naveen Thacker, MBBS, MD
Vipin M Vashistha, MD
Sujeet Jain, MBBS
Stephen Sosler, MD
Ajay Khera, MBBS, MD
Order of Authors Secondary Information:
Abstract: Abstract:
'Adverse event following immunization' (AEFI) is a critical component of immunizationprogram. The risk of AEFI with vaccination is always weighed against the risk of notimmunizing a child. The vaccination programs work in a paradox and when thevaccination coverage increases and disease burden reduces drastically, more cases ofAEFI attract the attention of the people than the disease in the community. AEFIsurveillance, therefore, helps to preserve public confidence in the immunizationprogramme. There is an evolving AEFI surveillance system in India for the vaccinesdelivered through 'universal immunization program' (UIP) of government sector, but thereporting remained suboptimal for long in the country, and there is almost noparticipation from private sector. The AEFI reporting from private sector will providevital information on the safety of new and underutilized vaccines, not part of the UIP inIndia. The national guidelines are recently revised and updated. The pediatricians, ingeneral, are not aware, and rather apprehensive about the existing AEFI reportingsystem and national guidelines on AEFI surveillance in India. This article is aimed tosensitize practitioners both in private and government sector on how to report cases,and outline the steps needed to improve AEFI surveillance and reporting bystrengthening public private partnership in India.
Key words: Adverse Event Following Immunization, surveillance, UniversalImmunization Program, public private partnership India.
Powered by Editorial Manager® and Preprint Manager® from Aries Systems Corporation
Perspective
Adverse Event Following Immunization (AEFI) Surveillance in
India: IAP’s Perspectives
Chitkara AJ*, Thacker N*, Vashishtha VM*, Jain S**, Sosler S**, Khera A***.
* From IAP Committee on Immunization, Indian Academy of Pediatrics;
**From National Polio Surveillance Project, Government of India;
***From Ministry of Health & Family Welfare, Government of India
Correspondence to:
Vipin M. Vashishtha,
Convener, IAP Committee on Immunization,
Mangla Hospital& Research Center,
Shakti Chowk,
Bijnor, Uttar Pradesh, 246701,India
Fax : 01342-265102
E mail: [email protected]
*Title Page
Adverse Event Following Immunization (AEFI) Surveillance in
India: IAP’s Perspectives
Introduction:
Immunization is one of the safest most cost effective interventions to improve child survival (1).
The advent and growing availability of new vaccines which target major childhood diseases such
as pneumonia, meningitis and rotavirus have the potential to save an additional 1.7 million child
lives. In India, with approximately 26 million infants born each year hundreds of millions doses
of vaccines are administered annually (2). Although vaccines are proven to be extremely safe,
there is risk of a potential adverse reaction as with any other drug or medication. The Adverse
Event Following Immunization (AEFI) is defined as ‘A medical incident that takes place after
immunization, causes concern and is believed to be caused by the immunization’ (4-5). This risk
of AEFI with vaccination is always weighed against the risk of not immunizing a child. It is only
when the benefit outweigh the risk, a vaccine is considered safe. However, even at a relatively
low rate, because of the high absolute number of beneficiaries, there is risk of a few serious
adverse events in the vaccinated children. This article to sensitize practitioners both in private
and government sector (including pediatricians) on how to report cases, and outline the steps
needed to improve AEFI surveillance and reporting by strengthening public private partnership
in India.
Why ‘Adverse Events Following Immunization’ are important?
The vaccines are foreign for human bodies, given to healthy infants and children. In the natural
process of developing immunity, a vaccine may cause fever, erythema, local pain etc. Besides,
*Blinded ManuscriptClick here to view linked References
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
there is a slight risk of foreign body reaction to the components in the vaccines. These factors are
likely to cause some concerns in the caregivers/parents. Whatever the cause, an AEFI may upset
people to the extent that they may refuse further vaccination for their children. This may lead to
the children much more likely to get a vaccine preventable disease, become seriously ill,
disabled, and risk death. AEFI surveillance, therefore, helps to preserve public confidence in the
immunization programme (4). Though, the majorities of AEFIs are mild, settle without
treatment, and have no long term consequences; very rarely, serious adverse reaction can occur.
The vaccination programs work in a paradox and when the vaccination coverage increases and
disease burden reduces drastically, more cases of AEFI attract the attention of the people than the
disease in the community (6).
AEFI surveillance strengthening in India:
AEFI surveillance in India started with the launch of Universal Immunization Program (UIP) in
1985. However, the AEFI reporting remained suboptimal for long in the country. In 2005/2006,
the Govt. of India, with technical assistance from the World Health Organization/National Polio
Surveillance Project India and other development partners, prepared the National AEFI
Surveillance and Response Operational Guidelines (7). These guidelines were widely
disseminated across the country among medical officers in Government sector. Since then many
state National, state and district level AEFI surveillance workshops for immunization program
managers have been conducted. The national guidelines were further revised and updated in
2010. These efforts have contributed in improving AEFI surveillance in India and the country
reported the highest ever of serious AEFI cases in 2010 (395 vs. 55 in 2006) (Figure 1).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
National AEFI guidelines in India:
There are 2 sets of national guidelines are available in India. The detailed version is called
operational guidelines, and a shorter version is for Standard Operating Procedures (8, 9). These
guidelines, based upon World Health Organization suggested framework (4), were developed
through a consultative process with various stakeholders, including various Government
departments involved in immunization program, state Govt. program managers, academic
institutions, independent subject experts, DCGI officials, development partners etc.
The AEFI reactions can broadly be classified as serious AEFIs (Death, disability &
hospitalization) which need to be reported immediately and investigated as per the laid down
procedures. The other AEFIs are reported through monthly reporting systems in UIP in GoI .
From the programmatic purpose, the AEFIs are classified in 5 broad categories of programmatic
error, vaccine reaction, injection reactions; coincidental and unknown.
How to report AEFI from private sector?
The majority of children in India receive immunization through public health facilities. However,
it is estimated that approx 10-20% of total immunization is provided through private sector and
by pediatricians (10). Moreover, the vaccines not part of the UIP in India are provided by the
private sector only. There is an evolving AEFI surveillance system in India for UIP vaccine from
Government sector; however, the reporting from private sector is limited so far. It is important
that AEFI from this sector are also reported and investigated, as per the laid down national
guidelines, which are applicable to private sector also. Additionally, the AEFI reporting from
private sector will provide vital information on the safety of new and underutilized vaccines in
India. Once a serious AEFI happens in the private sector at a clinic of pediatricians, in the rural
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
area, she/he should immediately inform medical officer in charge of nearest Primary Health
centre or other health facility. In the Urban area, either she/he can inform Medical Officer In
charge of nearest Urban Health Centre or to the District Immunization officer (DIO). By all
channel, the information should reach DIO as soon as possible.
The private practitioners (including pediatricians) should use the FIR form for reporting serious
AEFI cases to the district officials. Once an AEFI is reported from private sector, the DIO and
district AEFI committee members would then investigate the reported AEFI case. The
Pediatricians should help the investigation team in collection of all the related information.
It has come out from various interactions at different forums that the pediatricians, in general, are
not aware and apprehensive about the existing AEFI reporting system and national guidelines on
AEFI surveillance and response in India.
The way forward:
Based upon the understanding of the AEFI surveillance and case investigation in India and a
series of interactions with members of professional bodies, there are a few possible ways to
strengthen AEFI reporting from private sector in India:
Stronger collaboration: Considering a large number of pediatricians provide
immunization service, their involvement in AEFI surveillance is crucial. A stronger
collaboration between Govt. of India and Indian Academy of Pediatrics (IAP) will be a
right platform to strengthen AEFI surveillance in India. The possible role of IAP can be
as follows:
Sensitizing members about AEFI surveillance in monthly IAP meetings
and through their state and national level conferences;
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
Disseminating information through IAP publications
Sensitizing members through annual conferences etc.
Reporting AEFIs and supporting case investigation
IAP members actively participating in District and state AEFI committee
activities
Supporting causality assessment at the state level.
Online AEFI reporting platform for private practitioners: A possible solution for
AEFI reporting from private sector is providing online platform through which
practitioners can report from the comfort of their clinic. This platform may ask for First
investigation report to be provided by Private Practitioner (PP) and then Government
counterpart can take lead and collaborate for further investigating and taking up the AEFI
case investigation and reporting.
IAP through its IAPCOI has resolved to collaborate with the National AEFI
program by suggesting the following measures:
o Integrate IAP disease surveillance project IDSURV with AEFI reporting for a
web based and IVR reporting (Already incorporated: idsurv.org).
o The IDSURV program is fine tuned to automatically send information to the
concerned DIO/SIO for prompt action.
o In due course SMS reporting shall also be integrated within the program for
preliminary reporting but shall have to be followed up by proper FIR.
The proposed PPP has been enthusiastically received by MOH, GOI for prompt
implementation.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
The PPP envisages continuous monitoring by all the stake holders for a meaningful
outcome.
Bringing the confidence amongst Pvt. Practitioners: Once the practitioners are
sensitized about the AEFI surveillance, they might have better confidence to report the
cases. Inculcating confidence in the private practitioners will contribute to strengthen
AEFI surveillance in India.
Conclusions:
The immunization coverage in India is slowly increasing and additional new and underutilized
vaccines are being administered to the children by private practitioners. While there is a system
for AEFI reporting from Govt. sector in India based on the operational guidelines, there is
limited awareness about the reporting system in the private sector resulting in inadequate
reporting. There is, thus, a perceived need for improving AEFI surveillance in the private sector.
This is possible through information dissemination and better collaboration with professional
bodies and GoI. The improved AEFI surveillance and reporting system in India will go in a long
way to increase and retain the faith of the community in the existing and new vaccines and
increasing the immunization coverage in India.
Conflicts of interests: None declared
Funding: None
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
REFERENCES:
1. WHO, UNICEF, World Bank. State of World Vaccines and Immunization. 3rd
Edition,
Geneva, World Health Organization, 2009.
2. CDC. Global routine vaccine coverage, 2010. Mord Mort Wkly Rep 2011; 60: 1520-5.
3. Black RE, Counsens S, Johnson HL, Lawn JE, Rudan I, Bassani DG et al. Global,
regional and national causes of child mortality in 2008: a systematic analysis. Lancet
2010; 375: 1969-87.
4. World Health Organization. Surveillance of Adverse Events following Immunziation:
field guide for managers of immunization programs. World Health Organization, Geneva.
1997.
5. World Health Organization. Aide memoir on AEFI investigation. World Health
Organization, Geneva. 2005.
6. Chen RT, Rastogi SC, Mullen JR, Hayes SW, Cochi SL, Donlon JA et al. The vaccine
adverse event reporting system (VAERS). Vaccine 1994; 12: 542-50.
7. Government of India. Adverse Events Following Immunization: surveillance and
response operational guidelines. MoHFW, GoI, 2006.
8. Government of India. Adverse Events Following Immunization: surveillance and
response operational guidelines. MoHFW, GoI, 2010.
9. Government of India. Adverse Events Following Immunization: surveillance and
response Standard operating procedures. MoHFW, GoI, 2010.
10. Government of India. Multi Year Strategic Plan (MYP) for UIP of India 2005-10.
MoHFW, GoI, 2010.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65
Figure 1: Reported Serious AEFIs in India (2005-11)
Reported Serious AEFI Cases (1999 - 2011) ( th Data as on Jan 2012)
0 3 9 9
29 48
80
170
32
290
199
395
301
0
50
100
150
200
250
300
350
400
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
*data does not include serious AEFI cases reported in JE campaigns conducted in endemic states
Source : As per available records with MOHFW, GoI
AEFI state workshops
Figure
Annexure I
Authorship Criteria and Responsibility, Financial Disclosure, Acknowledgment, and Copyright
Transfer Form Manuscript no.
Manuscript Title: Adverse Event Following Immunization (AEFI) Surveillance in India: IAP’s
Perspectives
I/We certify that the manuscript represents valid work and that neither this manuscript nor one with
substantially similar content under my/our authorship has been published or is being considered for
publication elsewhere. For papers with more than 1 author, We agree to allow the corresponding author to
serve as the primary correspondent with the editorial office, to review the edited typescript and proof.
I/We have seen and approved the submitted manuscript. All of us have participated sufficiently in the
work to take public responsibility for the contents. All the authors have made substantial contributions to
the intellectual content of the paper and fulfil at least 1 condition for each of the 3 categories of
contributions: i.e., Category 1 (conception and design, acquisition of data, analysis and interpretation of
data), Category 2 (drafting of the manuscript, critical revision of the manuscript for important intellectual
content) and Category 3 (final approval of the version to be published).
I/We also certify that all my/our affiliations with or financial involvement with any organization or entity
with a financial interest in or financial conflict with the subject matter or materials discussed in the
manuscript are completely disclosed on the title page of the manuscript. My/our right to examine,
analyze, and publish the data is not infringed upon by any contractual agreement.
I/We certify that all persons who have made substantial contributions to the work reported in this
manuscript (e.g., data collection, writing or editing assistance) but who do not fulfill the authorship
criteria are named along with their specific contributions in an acknowledgment section in the manuscript.
If an acknowledgment section is not included, no other persons have made substantial contributions to
this manuscript. I/We also certify that all persons named in the acknowledgment section have provided
written permission to be named.
The author(s) undersigned hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership,
including any and all rights incidental thereto, exclusively to the Indian Pediatrics, in the event that such
work is published in Indian Pediatrics.
Authors’ name(s) in order of appearance in the manuscript Signatures (date)
1-Amarjeet Chitkara
2-Naveen Thacker
3-Vipin M. Vashishtha
4-Sujeet Jain
5-Stephen Sosler
6-Ajay Khera
*Copyright Transfer Form